TY - JOUR
T1 - Effect of immune activation on the kynurenine pathway and depression symptoms – A systematic review and meta-analysis
AU - Hunt, Charlotte
AU - Macedo e Cordeiro, Thiago
AU - Suchting, Robert
AU - de Dios, Constanza
AU - Cuellar Leal, Valeria A.
AU - Soares, Jair C.
AU - Dantzer, Robert
AU - Teixeira, Antonio L.
AU - Selvaraj, Sudhakar
N1 - Funding Information:
The University of Texas Health Science Center at Houston research supplement funds to S.S were utilized for this study. The University of Texas Health Science Center at Houston had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. R.D received a NARSAD Distinguished Investigator Award and is funded by grants from the National Institutes of Health (R01 CA193522 and R01 NS073939), and an MD Anderson Cancer Support Grant (P30 CA016672). The content of this study is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
Publisher Copyright:
© 2020 Elsevier Ltd
PY - 2020/11
Y1 - 2020/11
N2 - Dysregulated kynurenine (KYN) pathway has been implicated in the pathophysiology of depression. In this systematic review, we examined the relationship between kynurenine pathway metabolites (KYN, kynurenic acid KYNA, tryptophan TRP, quinolinic acid QUIN, KYN/TRP ratio) and depression symptoms in the context of pro-inflammatory activation and immune response. Out of 5,082 articles, fifteen studies were suitable; ten studies (N = 315 medically ill patients treated with interferon-alpha IFN-α) reported baseline and post-intervention plasma KYN, TRP and KYN/TRP ratios which were included in quantitative meta-analysis. Data from five studies were summarized (IFN-α, interferon-beta IFN-β, and lipopolysaccharide LPS). We found that IFN-α treatment in patients with chronic illnesses was associated with decreased TRP, increased levels of KYN and KYN/TRP ratio and depression scores from baseline to follow-up at both 4 and 24 weeks. Our findings suggest that increased risk of depression observed after immune-activating agents in patients with chronic medical illnesses is likely mediated by the kynurenine pathway. Further prospective studies are required to investigate the exact pathophysiology of the KYN pathway in depression.
AB - Dysregulated kynurenine (KYN) pathway has been implicated in the pathophysiology of depression. In this systematic review, we examined the relationship between kynurenine pathway metabolites (KYN, kynurenic acid KYNA, tryptophan TRP, quinolinic acid QUIN, KYN/TRP ratio) and depression symptoms in the context of pro-inflammatory activation and immune response. Out of 5,082 articles, fifteen studies were suitable; ten studies (N = 315 medically ill patients treated with interferon-alpha IFN-α) reported baseline and post-intervention plasma KYN, TRP and KYN/TRP ratios which were included in quantitative meta-analysis. Data from five studies were summarized (IFN-α, interferon-beta IFN-β, and lipopolysaccharide LPS). We found that IFN-α treatment in patients with chronic illnesses was associated with decreased TRP, increased levels of KYN and KYN/TRP ratio and depression scores from baseline to follow-up at both 4 and 24 weeks. Our findings suggest that increased risk of depression observed after immune-activating agents in patients with chronic medical illnesses is likely mediated by the kynurenine pathway. Further prospective studies are required to investigate the exact pathophysiology of the KYN pathway in depression.
KW - Depression
KW - Inflammation
KW - Interferon
KW - Kynurenic acid
KW - Kynurenine
KW - Mood disorder
KW - Tryptophan
UR - http://www.scopus.com/inward/record.url?scp=85090186085&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85090186085&partnerID=8YFLogxK
U2 - 10.1016/j.neubiorev.2020.08.010
DO - 10.1016/j.neubiorev.2020.08.010
M3 - Review article
C2 - 32853625
AN - SCOPUS:85090186085
SN - 0149-7634
VL - 118
SP - 514
EP - 523
JO - Neuroscience and Biobehavioral Reviews
JF - Neuroscience and Biobehavioral Reviews
ER -